当前位置: 首页 > 期刊 > 《医学信息》 > 2016年第12期
编号:12836435
miR—150促进鼻咽癌细胞放疗抵抗(2)
http://www.100md.com 2016年3月26日 《医学信息》 2016年第12期
     参考文献:

    [1]DeNittis AS, Liu L, Rosenthal DI, et al. Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy [J]. Am J Clin Oncol, 2002, 25 (1): 93-95.

    [2]HC Chen, GH Chen, YH Chen, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma[J].British Journal of Cancer, 2009, 100:1002-1011.

    [3]Rui W, Bing F, Hai-Zhu S,et al.Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1) [J].J Cell Mol Med, 2010, 14(1-2): 206-214.

    [4]Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy [J]. Clin Cancer Res, 2009, 15(16): 5060-5072.

    [5]Sun L, Yao Y, Liu B, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1 [J]. Oncogene, 2012, 31(4): 432-445.

    编辑/安桦, 百拇医药(张先锋 黄远见 肖娟)
上一页1 2